Unique ID issued by UMIN | UMIN000014292 |
---|---|
Receipt number | R000016642 |
Scientific Title | Study of antimicrobial lock therapy for catheter-related bloodstream infection in totally implantable central venous port |
Date of disclosure of the study information | 2014/07/28 |
Last modified on | 2016/06/17 16:13:18 |
Study of antimicrobial lock therapy for catheter-related bloodstream infection in totally implantable central venous port
Study of antimicrobial lock therapy
Study of antimicrobial lock therapy for catheter-related bloodstream infection in totally implantable central venous port
Study of antimicrobial lock therapy
Japan |
Case of catheter-related bloodstream infection in totally implantable central venous port
Infectious disease | Surgery in general | Gastrointestinal surgery |
Others
NO
The purpose of the study is to assess the efficacy and safety of antimicrobial lock therapy for catheter-related bloodstream infection in totally implantable central venous port.
Safety,Efficacy
To evaluate the efficacy of antimicrobial lock therapy for catheter-related bloodstream infection in totally implantable central venous port.
To evaluate the safety of antimicrobial lock therapy for catheter-related bloodstream infection in totally implantable central venous port.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
3mL of mixed drug solution (Caspofungin 2.5mg/mL and Daptomycin 50mg/mL) was inserted to the central venous catheter port. Insertion was performed by 24 hours.
When the result of blood culture was detected, the drug solution was changed (Caspofungin 2.5mg/mL, Daptomycin 50mg/mL, or amikacin sulfate 100mg/mL). Insertion was performed by 24 hours for 14 days from the first lock therapy.
20 | years-old | <= |
Not applicable |
Male and Female
1. Patients who underwent home parenteral nutrition by totally implantable central venous port.
2. fever more than 38.0 degree.
3. catheter-related bloodstream infection is suspected.
4. No severe complication by sepsis. General condition is good.
5. No allergy for antimicrobial drugs which will be used in this study.
1.Patients with severe sepsis
2.Patients who underwent lock therapy for bacterial infection within 3 months
3.Patients who underwent lock therapy for fungal infection
4.Patients with pregnancy
5.Patients who doctors regarded as inadequate to participate this study.
30
1st name | |
Middle name | |
Last name | Kazuhiro Watanabe |
Tohoku University Hospital
Gastrointestinal Surgery
1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi
022-717-7205
k-wata@surg1.med.tohoku.ac.jp
1st name | |
Middle name | |
Last name | Kazuhiro Watanabe |
Tohoku University Hospital
Gastrointestinal Surgery
1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi
022-717-7205
k-wata@surg1.med.tohoku.ac.jp
Division of Gastrointestinal Surgery, Tohoku University Hospital
Division of Gastrointestinal Surgery, Tohoku University Hospital
Other
NO
2014 | Year | 07 | Month | 28 | Day |
Unpublished
Enrolling by invitation
2014 | Year | 06 | Month | 17 | Day |
2014 | Year | 08 | Month | 01 | Day |
2014 | Year | 06 | Month | 17 | Day |
2016 | Year | 06 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016642